Morgan Stanley Boosts Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target to $11.00

Centessa Pharmaceuticals (NASDAQ:CNTAFree Report) had its target price upped by Morgan Stanley from $8.00 to $11.00 in a research report report published on Friday morning, Benzinga reports. The firm currently has an equal weight rating on the stock.

Separately, BMO Capital Markets restated an outperform rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of Moderate Buy and a consensus price target of $10.50.

View Our Latest Report on CNTA

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $9.10 on Friday. The firm has a market capitalization of $914.37 million, a P/E ratio of -6.41 and a beta of 1.39. The stock has a fifty day moving average price of $9.18 and a 200 day moving average price of $9.22. Centessa Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $12.45. The company has a current ratio of 10.37, a quick ratio of 10.37 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. Equities research analysts anticipate that Centessa Pharmaceuticals will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CNTA. Rathbones Group PLC purchased a new stake in shares of Centessa Pharmaceuticals in the third quarter worth about $203,000. Affinity Asset Advisors LLC boosted its position in shares of Centessa Pharmaceuticals by 13.0% in the third quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock worth $6,587,000 after buying an additional 117,368 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of Centessa Pharmaceuticals by 25.8% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock worth $18,313,000 after buying an additional 580,500 shares during the period. Acuta Capital Partners LLC purchased a new position in Centessa Pharmaceuticals in the third quarter valued at about $2,092,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 371.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after purchasing an additional 5,037 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

Featured Stories

Analyst Recommendations for Centessa Pharmaceuticals (NASDAQ:CNTA)

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.